Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP
Go back to Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP| Regeneron (NASDAQ: REGN) | Delayed: 827.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $827.72 | 52 Week High | $592.36 | |||
| Open | $827.72 | 52 Week Low | $325.35 | |||
| Day High | $827.72 | P/E | 217.25 | |||
| Day Low | $827.72 | EPS | $3.81 | |||
| Volume | 464 | |||||
